NDAINTRAVENOUSSOLUTION
Approved
Nov 2020
Lifecycle
Peak
Competitive Pressure
30/100
Mechanism of Action
alpha1-adrenergic blocking and competitive beta-adrenergic blocking activity. In man, the ratio of alpha- to beta-blockade has been estimated to be approximately 1:7 following intravenous administration. Beta 2 -agonist activity has been demonstrated in animals with minimal beta 1 -agonist activity…